Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Study Design in Statistics01:15

Study Design in Statistics

A study design is a set of techniques that allow a researcher to collect and analyze data from different variables defined for a specific research problem. Statistics is commonly for effective study design and more robust experiments,
Does aspirin reduce the risk of heart attacks? Is one brand of fertilizer more effective at growing roses than another? Is fatigue as dangerous to a driver as the influence of alcohol? Questions like these are answered using randomized experiments with proper...
Experimental Designs01:16

Experimental Designs

An experimental design is a systematic process that allows researchers to evaluate the relationship between dependent and independent variables. There are three widely used types of experimental design - pre-experimental design, true experimental design, and quasi-experimental design. In pre-experimental design, the researcher compares the data before and after some interventions or treatments. The true-experimental design has more than one purposefully created group, a commonly measured...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
Randomized Experiments01:13

Randomized Experiments

The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Semi-automatic mask guidance enhances 3D tumor segmentation in medical imaging.

Communications medicine·2026
Same author

Empowering multifaceted analysis of spatial transcriptomics data with RGAST.

Briefings in bioinformatics·2026
Same author

Evaluating the Effectiveness of an Enhanced Early Childhood Development Program Integrated Into Primary Health Care in China: Protocol for a Cluster Randomized Controlled Trial.

JMIR research protocols·2026
Same author

A Bayesian phase I/II platform design with survival efficacy endpoint for dose optimization.

Statistical methods in medical research·2026
Same author

Meta-encoder: a unified integration framework for multiple pathological foundation models in cancer detection.

Nature communications·2026
Same author

Association Between Renal Dysfunction and Cerebral Small Vessel Disease: A Prospective Cohort Study From the UK Biobank.

CNS neuroscience & therapeutics·2026
Same journal

Causally-interpretable random-effects meta-analysis.

Biometrics·2026
Same journal

Statistical inference for mean function of partially observed functional time series.

Biometrics·2026
Same journal

Subgroup identification via Interaction Tree and Mixed Model for Repeated Measures with application to Alzheimer's disease.

Biometrics·2026
Same journal

Finite mixtures of linear quantile regressions with concomitant variables: a solution to endogeneity in longitudinal data modeling.

Biometrics·2026
Same journal

Discussion on "INTACT: a method for integration of longitudinal physical activity data from multiple sources" by Jingru Zhang, Erjia Cui, Hongzhe Li, and Haochang Shou.

Biometrics·2026
Same journal

Rejoinder to the discussion on "INTACT: A method for integration of longitudinal physical activity data from multiple sources".

Biometrics·2026
See all related articles
  1. Home
  3. A Bayesian Phase I/ii Platform Design With Data Augmentation Accounting For Delayed Outcomes.
  1. Home
  3. A Bayesian Phase I/ii Platform Design With Data Augmentation Accounting For Delayed Outcomes.

Related Experiment Video

Bringing the Clinic Home: An At-Home Multi-Modal Data Collection Ecosystem to Support Adaptive Deep Brain Stimulation
06:32

Bringing the Clinic Home: An At-Home Multi-Modal Data Collection Ecosystem to Support Adaptive Deep Brain Stimulation

Published on: July 14, 2023

A Bayesian phase I/II platform design with data augmentation accounting for delayed outcomes.

Wentao Yang1, Rongji Mu2, Zhangsheng Yu1,2

  • 1School of Mathematical Sciences, Shanghai Jiao Tong University, Shanghai 200240, PR China.

Biometrics
|June 19, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

This study introduces a Bayesian trial design (BPDD) using data augmentation to handle delayed outcomes in drug development. It improves dose selection efficiency and accuracy for multi-indication platform trials.

Keywords:
Bayesian adaptive designdata augmentation methoddose optimizationplatform trial

Related Experiment Videos

Bringing the Clinic Home: An At-Home Multi-Modal Data Collection Ecosystem to Support Adaptive Deep Brain Stimulation
06:32

Bringing the Clinic Home: An At-Home Multi-Modal Data Collection Ecosystem to Support Adaptive Deep Brain Stimulation

Published on: July 14, 2023

Area of Science:

  • Clinical Trials
  • Pharmacometrics
  • Biostatistics

Background:

  • Delayed outcomes (toxicity, efficacy) complicate dose optimization in Bayesian phase I/II platform trials.
  • Accurate and timely dose selection is crucial for multi-indication drug development.

Purpose of the Study:

  • To propose an enhanced Bayesian phase I/II platform design (BPDD) with data augmentation for delayed outcomes.
  • To improve dose selection efficiency and accuracy in multi-indication trials.

Main Methods:

  • Developed the Bayesian phase I/II platform design with data augmentation (BPDD).
  • Employed iterative data augmentation to predict unobserved outcomes.
  • Utilized hierarchical modeling for cross-indication information sharing.

Main Results:

  • BPDD refines dose-toxicity and dose-efficacy estimates using observed and imputed data.
  • Demonstrated significant reduction in clinical trial time.
  • Simulation studies confirmed robustness, accuracy, and time efficiency.

Conclusions:

  • The BPDD framework effectively manages delayed outcomes in multi-indication platform trials.
  • Enhances clinical trial efficiency and accelerates drug development.
  • Improves decision-making for dose escalation, de-escalation, and optimal biological dose identification.